Price
No data yet.
Social Signal Score
Analyst Ratings
6 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Dietrich John Pauls
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 35
- Beta
- 0.97
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- 32.19
Financials
Revenue
$0.00-100.0%Net Income
$-10.14MEBITDA
$-9.75MFree Cash Flow
$-8.12MEPS (diluted)
$-0.19Shares Outstanding (diluted)
53.89M+1022.3%Operating Expenses
$10.50MCash & Debt
$43.50MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-32.77M | $-0.70 |
| 2024 | $0.00 | $-24.44M | $-0.60 |
| 2023 | $0.00 | $-19.38M | $-0.60 |
| 2022 | $0.00 | $-13.68M | $-0.52 |
| 2021 | $0.00 | $-13.59M | $-0.65 |
| 2020 | $0.00 | $-12.29M | $-0.78 |
| 2019 | $0.00 | $-10.65M | $-0.89 |
| 2018 | $500.0K | $-5.73M | $-0.74 |
| 2017 | $0.00 | $-4.26M | $-0.72 |
| 2016 | $0.00 | $-2.22M | $-0.47 |
| 2015 | $0.00 | $-1.44M | $-0.40 |
| 2014 | $0.00 | $-4.82M | $-1.55 |
| 2013 | $0.00 | $-7.41M | $-2.71 |
| 2012 | $0.00 | $-10.05M | $-4.11 |
Valuation
DMAChas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50+0.00%Social Signal Score
Mentions (5)
- Newszacks.com·40d ago·Neutral
Wall Street Analysts Think DiaMedica Therapeutics (DMAC) Could Surge 129.97%: Read This Before Placing a Bet The average of price targets set by Wall Street analysts indicates a potential upside of 130% in DiaMedica Therapeutics (DMAC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
View source ↗ - Newszacks.com·53d ago·Positive
All You Need to Know About DiaMedica Therapeutics (DMAC) Rating Upgrade to Buy DiaMedica Therapeutics (DMAC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
View source ↗ - Newsseekingalpha.com·55d ago·Positive
DiaMedica Therapeutics Inc. (DMAC) Q2 2026 Earnings Call Transcript DiaMedica Therapeutics Inc. (DMAC) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·56d ago·Negative
DiaMedica Therapeutics Q2 Earnings Call Highlights DiaMedica Therapeutics NASDAQ: DMAC said its second-quarter progress centered on advancing DM199 across early-onset fetal growth restriction (FGR), preeclampsia and acute ischemic stroke, while the company reported a cash runway it expects to extend through 2027.
View source ↗ - Newsbusinesswire.com·56d ago·Neutral
DiaMedica Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today provided a business update and reported financial results for the second quarter ended June 30, 2026. Management will host a conference call Tuesday, August 11, 2026,
View source ↗
Earnings
Wed, Nov 11(in 5 weeks)
Consensus estimate $-0.20 per share
Typical surprise +0.0% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 10$-0.19 vs $-0.20beat
- Wed, May 6$-0.19 vs $-0.17miss
- Mon, Mar 30$-0.17 vs $-0.17beat
- Wed, Nov 12$-0.17 vs $-0.15miss
- Tue, Aug 12$-0.18 vs $-0.18beat
- Tue, May 13$-0.18 vs $-0.18beat
Estimates and results for DMAC via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by DMAC officers and directors.
- Bought
- $42.9m
- Sold
- —
30 trades
0 trades
- Stahlberg Janbought
- Stahlberg Janbought
- Stahlberg Janbought
- Stahlberg Janbought
- Stahlberg Janbought
- Stahlberg Janbought
- Stahlberg Janbought
- Stahlberg Janbought
70 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in DMAC.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.